Document Detail


Tissue factor pathway inhibitor blocks angiogenesis via its carboxyl terminus.
MedLine Citation:
PMID:  22223730     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Tissue factor pathway inhibitor (TFPI) is the primary regulator of the tissue factor (TF) coagulation pathway. As such, TFPI may regulate the proangiogenic effects of TF. TFPI may also affect angiogenesis independently of TF, through sequences within its polybasic carboxyl terminus (TFPI C terminus [TFPIct]). We aimed to determine the effects of TFPI on angiogenesis and the role of TFPIct.
METHODS AND RESULTS: Transgenic overexpression of TFPI attenuated angiogenesis in the murine hindlimb ischemia model and an aortic sprout assay. In vitro, TFPI inhibited endothelial cell migration. Peptides within the human TFPIct inhibited endothelial cell cord formation and migration in response to vascular endothelial growth factor (VEGF) 165 but not VEGF121. Furthermore, exposure to human TFPIct inhibited the phosphorylation of VEGF receptor 2 at residue Lys951, a residue known to be critical for endothelial cell migration. Finally, systemic delivery of a murine TFPIct peptide inhibited angiogenesis in the hindlimb model.
CONCLUSION: These data demonstrate an inhibitory role for TFPI in angiogenesis that is, in part, mediated through peptides within its carboxyl terminus. In addition to its known role as a TF antagonist, TFPI, via its carboxyl terminus, may regulate angiogenesis by directly blocking VEGF receptor 2 activation and attenuating the migratory capacity of endothelial cells.
Authors:
Eric W Holroyd; Sinny Delacroix; Katarina Larsen; Adriana Harbuzariu; Peter J Psaltis; Ling Wang; Shuchong Pan; Thomas A White; Tyra A Witt; Laurel S Kleppe; Cheryl S Mueske; Debabrata Mukhopadhyay; Robert D Simari
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-01-05
Journal Detail:
Title:  Arteriosclerosis, thrombosis, and vascular biology     Volume:  32     ISSN:  1524-4636     ISO Abbreviation:  Arterioscler. Thromb. Vasc. Biol.     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-02-20     Completed Date:  2012-04-13     Revised Date:  2013-03-11    
Medline Journal Info:
Nlm Unique ID:  9505803     Medline TA:  Arterioscler Thromb Vasc Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  704-11     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Diseases, Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / chemistry,  deficiency,  genetics,  metabolism*,  pharmacology
Animals
Binding Sites
Cell Movement
Disease Models, Animal
Heparin / metabolism
Hindlimb
Human Umbilical Vein Endothelial Cells / metabolism
Humans
Ischemia / genetics,  metabolism*,  physiopathology
Lipoproteins / chemistry,  deficiency,  genetics,  metabolism*,  pharmacology
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Microfilament Proteins / genetics
Muscle Proteins / genetics
Muscle, Skeletal / blood supply*
Neovascularization, Physiologic* / drug effects
Peptides / pharmacology
Phosphorylation
Promoter Regions, Genetic
Protein Structure, Tertiary
Time Factors
Vascular Endothelial Growth Factor Receptor-2 / metabolism
Grant Support
ID/Acronym/Agency:
HL 65191/HL/NHLBI NIH HHS; R01 HL065191-10/HL/NHLBI NIH HHS; R01 HL070567/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Lipoproteins; 0/Microfilament Proteins; 0/Muscle Proteins; 0/Peptides; 0/Tagln protein, mouse; 0/lipoprotein-associated coagulation inhibitor; 9005-49-6/Heparin; EC 2.7.10.1/Vascular Endothelial Growth Factor Receptor-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Urotensin-II Signaling Mechanism in Rat Coronary Artery: Role of STIM1 and Orai1-Dependent Store Ope...
Next Document:  Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosi...